Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features
- PMID: 22915760
- PMCID: PMC3763938
- DOI: 10.1158/0008-5472.CAN-12-1615
Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features
Abstract
Mantle cell lymphoma (MCL) is a heterogeneous disease with most patients following an aggressive clinical course, whereas others having an indolent behavior. We conducted an integrative and multidisciplinary analysis of 177 MCL to determine whether the immunogenetic features of the clonotypic B-cell receptors (BcR) may identify different subsets of tumors. Truly unmutated (100% identity) IGHV genes were found in 24% cases, 40% were minimally/borderline mutated (99.9%-97%), 19% significantly mutated (96.9%-95%), and 17% hypermutated (<95%). Tumors with high or low mutational load used different IGHV genes, and their gene expression profiles were also different for several gene pathways. A gene set enrichment analysis showed that MCL with high and low IGHV mutations were enriched in memory and naive B-cell signatures, respectively. Furthermore, the highly mutated tumors had less genomic complexity, were preferentially SOX11-negative, and showed more frequent nonnodal disease. The best cut-off of germline identity of IGHV genes to predict survival was 97%. Patients with high and low mutational load had significant different outcome with 5-year overall survival (OS) of 59% and 40%, respectively (P = 0.004). Nodal presentation and SOX11 expression also predicted for poor OS. In a multivariate analysis, IGHV gene status and SOX11 expression were independent risk factors. In conclusion, these observations suggest the idea that MCL with mutated IGHV, SOX11-negativity, and nonnodal presentation correspond to a subtype of the disease with more indolent behavior.
Conflict of interest statement
Figures
Similar articles
-
Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma.Cancer Res. 2010 Feb 15;70(4):1408-18. doi: 10.1158/0008-5472.CAN-09-3419. Epub 2010 Feb 2. Cancer Res. 2010. PMID: 20124476
-
SOX11, a key oncogenic factor in mantle cell lymphoma.Curr Opin Hematol. 2018 Jul;25(4):299-306. doi: 10.1097/MOH.0000000000000434. Curr Opin Hematol. 2018. PMID: 29738333 Review.
-
microRNA expression profiles identify subtypes of mantle cell lymphoma with different clinicobiological characteristics.Clin Cancer Res. 2013 Jun 15;19(12):3121-9. doi: 10.1158/1078-0432.CCR-12-3077. Epub 2013 May 2. Clin Cancer Res. 2013. PMID: 23640973 Free PMC article.
-
Leukemic Variant of Mantle Cell Lymphoma: Clinical Presentation and Management.Curr Oncol Rep. 2021 Jul 16;23(9):102. doi: 10.1007/s11912-021-01094-y. Curr Oncol Rep. 2021. PMID: 34269910 Review.
-
A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.Blood. 2003 Jun 15;101(12):4975-81. doi: 10.1182/blood-2002-06-1864. Epub 2003 Feb 27. Blood. 2003. PMID: 12609845
Cited by
-
Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials.Leukemia. 2024 Sep 16. doi: 10.1038/s41375-024-02375-8. Online ahead of print. Leukemia. 2024. PMID: 39284897
-
Epidemiological, clinical and therapeutic profiles of mantle cell lymphoma cared for in a Moroccan center: a review of 14 cases.Pan Afr Med J. 2024 Mar 6;47:111. doi: 10.11604/pamj.2024.47.111.40405. eCollection 2024. Pan Afr Med J. 2024. PMID: 38828423 Free PMC article.
-
Biological and clinical determinants shaping heterogeneity in mantle cell lymphoma.Blood Adv. 2024 Jul 23;8(14):3652-3664. doi: 10.1182/bloodadvances.2023011763. Blood Adv. 2024. PMID: 38748869 Free PMC article. Review.
-
Identification of CD5/SOX11 double-negative pleomorphic mantle cell lymphoma.Virchows Arch. 2024 Aug;485(2):323-334. doi: 10.1007/s00428-024-03813-9. Epub 2024 May 11. Virchows Arch. 2024. PMID: 38733379
-
SOX11/PRDX2 axis modulates redox homeostasis and chemoresistance in aggressive mantle cell lymphoma.Sci Rep. 2024 Apr 3;14(1):7863. doi: 10.1038/s41598-024-58216-2. Sci Rep. 2024. PMID: 38570586 Free PMC article.
References
-
- Swerdlow S, Campo E, Harris N, Jaffe E, Pileri S, Stein H, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4. Lyon: 2008.
-
- Welzel N, Le T, Marculescu R, Mitterbauer G, Chott A, Pott C, et al. Templated nucleotide addition and immunoglobulin JH-gene utilization in t(11;14) junctions: implications for the mechanism of translocation and the origin of mantle cell lymphoma. Cancer Res. 2001;61:1629–36. - PubMed
-
- Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer. 2007;7:750–62. - PubMed
-
- Bea S, Campo E. Secondary genomic alterations in non-Hodgkin’s lymphomas: tumor-specific profiles with impact on clinical behavior. Haematologica. 2008;93:641–5. - PubMed
-
- Royo C, Salaverria I, Hartmann E, Rosenwald A, Campo E, Bea S. The complex landscape of genetic alterations in mantle cell lymphoma. Semin Cancer Biol. 2011;5:322–34. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources